Who is sponsoring NCT04313127?

NCT04313127 is sponsored by CanSino Biologics Inc..

What drugs are being tested in NCT04313127?

Interventions in NCT04313127: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector).

Is NCT04313127 still recruiting?

NCT04313127 is currently completed. Last updated 4 August 2021.

Last reviewed 2021-08-04 · How we verify

NCT04313127: CTCOVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults

Completed Phase 1 Last updated 4 August 2021

What this trial tests

Phase 1 trial testing Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in COVID-19 in 108 participants. Completed in 20 February 2021.

Timeline

16 March 2020

Primary endpoint
20 January 2021

20 February 2021

Quick facts

Lead sponsor	CanSino Biologics Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	prevention
Enrollment	108
Start date	16 March 2020
Primary completion	20 January 2021
Estimated completion	20 February 2021
Sites	1 location across China

Drugs / interventions tested

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

CanSino Biologics Inc. — full company profile →

Who can join

Adults 18 to 60, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The 2019 novel-coronavirus (2019-nCov) is the cause of a cluster of unexplained pneumonia that started in Hubei province in China. It has manifest into a global health crisis with escalating confirmed cases and spread across many countries. In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of diseases caused by COVID-19 can be tough for current treatment. This study is a phase I clinical trial. The investigators intent to evaluate the safety, reactogenicity and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) .

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunology of COVID-19: Current State of the Science.
Vabret N, Britton GJ, Gruber C, Hegde S, et al · · 2020 · cited 1248× · PMID 32505227 · DOI 10.1016/j.immuni.2020.05.002
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Zhu FC, Li YH, Guan XH, Hou LH, et al · · 2020 · cited 1017× · PMID 32450106 · DOI 10.1016/s0140-6736(20)31208-3
COVID-19 Vaccine: A comprehensive status report.
Kaur SP, Gupta V. · · 2020 · cited 482× · PMID 32800805 · DOI 10.1016/j.virusres.2020.198114
COVID-19: Transmission, prevention, and potential therapeutic opportunities.
Lotfi M, Hamblin MR, Rezaei N. · · 2020 · cited 447× · PMID 32474009 · DOI 10.1016/j.cca.2020.05.044
Impact of Vaccines; Health, Economic and Social Perspectives.
Rodrigues CMC, Plotkin SA. · · 2020 · cited 394× · PMID 32760367 · DOI 10.3389/fmicb.2020.01526
Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management.
D'Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. · · 2020 · cited 357× · PMID 32278065 · DOI 10.1016/j.cgh.2020.04.001
Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK, Firmal P, Alam A, Ganguly D, et al · · 2020 · cited 317× · PMID 32849654 · DOI 10.3389/fimmu.2020.01949
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.
Lythgoe MP, Middleton P. · · 2020 · cited 247× · PMID 32291112 · DOI 10.1016/j.tips.2020.03.006

Verify or expand the search:

Other trials of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Trials testing the same drug.

NCT05169008 — A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adoles · Phase 3 · terminated
NCT04840992 — Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation · Phase 1, PHASE2 · completed
NCT04566770 — A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) · Phase 2 · completed
NCT04526990 — Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above · Phase 3 · completed
NCT04540419 — Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 · Phase 3 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other CanSino Biologics Inc. trials

Trials by the same sponsor.

NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant · Phase 3 · recruiting
NCT06708286 — A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) · Phase 2, PHASE3 · active not recruiting
NCT06700148 — A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds · Phase 3 · active not recruiting
NCT06120751 — A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population · Phase 3 · completed
NCT06101173 — A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Health · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04313127 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CanSino Biologics Inc.
Last refreshed: 4 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04313127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing